Description: Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. It also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Home Page: www.bioventix.com
7 Romans Business Park
Farnham,
GU9 7SX
United Kingdom
Phone:
44 12 5272 8001
Officers
| Name | Title |
|---|---|
| Mr. Peter John Harrison MA | CEO & Director |
| Mr. Bruce Edward Heath Hiscock | CFO & Director |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 21.645 |
|---|---|
| Trailing PE: | 24.2391 |
| Price-to-Book MRQ: | 16.0917 |
| Price-to-Sales TTM: | 17.3801 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 12 |